We evaluated the effectiveness of the 2010-2011 seasonal influenza vaccine for preventing laboratory-confirmed influenza in a South Korean population. A retrospective case-control study was conducted among patients who visited selected hospitals from September 2010 to May 2011. A total of 483 laboratory-confirmed influenza patients were included in the analysis as case subjects. For each case patient, two types of control patients were chosen at a ratio of 1:1:1, and 966 control subjects were selected. Vaccine effectiveness (VE) was defined as 100 ؋ (1 ؊ odds ratio for influenza in vaccinated versus nonvaccinated persons). The VE of the 2010-2011 seasonal influenza vaccine was 49.5% to 45.8% for both influenza A and B viruses and 50.8% to 47.2% for influenza A virus, according to the control type. The age-specific adjusted VE was 50.8% to 46.5% among subjects aged 19 to 49 years and 58.7% to 63.3% among those aged 50 to 64 years, according to the control type. Statistically significant VE was not found among those aged >65 years or against influenza B virus. The 2010-2011 seasonal influenza vaccine was effective for preventing laboratory-confirmed influenza, especially for influenza A virus, in a South Korean population. Evidence of the effectiveness of the influenza vaccine in older adults or against influenza B virus was not found.
. There were some reports on the clinical effectiveness of the 2010-2011 influenza vaccine in a relatively small population of children (2) (3) (4) (5) .
The seasonal influenza vaccine has been used widely in South Korea, especially among the elderly (6) , and the need for the influenza vaccine has been increasing since the 2009 influenza pandemic. Groups at high risk for influenza, such as patients with chronic medical conditions or the elderly, are priority groups for influenza vaccination. The influenza vaccine has especially been given to the elderly free of charge by the government. Almost all of the influenza vaccines used for the elderly are traditional unadjuvanted split vaccines. However, studies on the effectiveness of the vaccine are lacking, and debate concerning vaccine use continues in South Korea.
This study evaluated the effectiveness of the 2010-2011 seasonal influenza vaccine for preventing laboratory-confirmed influenza virus infection in a population of South Korean adults.
MATERIALS AND METHODS

Study population and data collection.
A matched case-control study was conducted among patients who visited four university hospitals with influenza-like illness (ILI) from September 2010 to May 2011. ILI was defined as fever with cough, sore throat, or rhinorrhea. The patients with ILI were usually tested for influenza virus in the participating hospitals according to the physician's decision, especially in the emergency room or outpatient department. In this study, if a patient was an inpatient and ILI occurred after more than 48 h from the time of hospitalization, the patient was excluded. Patients Ն18 years of age with laboratory-confirmed influenza were selected as case patients. Laboratory-confirmed influenza was defined as a positive result from a rapid antigen test (RAT), PCR test, or influenza virus culture, regardless of when the symptoms started. For each case patient, two types of control (control 1 and 2) patients were chosen at a ratio of 1:1:1. A control 1 patient was defined as an age group-matched patient who visited the same hospital with ILI within 48 h of symptom onset but for whom laboratory tests were negative for influenza virus. A control 2 patient was defined as an age group-matched patient who visited the same clinic in the same hospital without ILI. Control 2 subjects visited the hospital for their underlying diseases or other acute diseases, such as acute gastroenteritis and cellulitis. Age group and visit date were matched between the case and both controls. All subjects were stratified into three age groups: 18 to 50, 51 to 64, and over 65 years. If two or more control subjects fulfilled the matching criteria, the subject with the smallest age difference from the case patient was selected from among them. If a selected control subject had an obscure influenza vaccination history or refused to have a telephone interview, a new control subject was chosen by use of the same criteria.
Data collection. Using a standardized questionnaire, the following data were collected for the subjects by reviewing their medical records: age, sex, clinical symptoms, date of symptom onset, date of clinic visits, vaccination status for the 2010-2011 season, diagnostic laboratory results for influenza, chronic medical conditions, and pregnancy and smoking status (current or previous smoker or nonsmoker). The patients were defined as having a chronic medical condition if they had any of the following: diabetes mellitus, cardiovascular disease, cerebrovascular disease, neuromuscular disease, chronic pulmonary disease, chronic renal disease, chronic hepatic disease, treatment for malignancy, congenital or acquired immunodeficiency, and medication with immunosuppressant agents. The 2010-2011 seasonal influenza vaccination history for each subject was checked by reviewing the medical records and conducting a telephone interview. We defined vaccinated individuals as those who had received the seasonal influenza vaccine before 14 days before the date of symptom onset.
Laboratory analysis. All four hospitals used the same laboratory methods for confirmation of influenza. Nasopharyngeal or throat swab specimens were used for the influenza laboratory tests. RAT was performed using a commercial kit, the SD Bioline influenza antigen test (Standard Diagnostic, Inc., South Korea), according to the manufacturer's instructions. PCR was performed using a commercial multiplex realtime PCR kit, the Anyplex II RV16 detection kit (Seegene, South Korea). An influenza virus culture was performed using an R-Mix Too (A549/ MDCK) shell vial culture. After the virus culture, immunofluorescence staining was performed using a Respiratory Virus Screening & ID kit (Dow Biomedical, South Korea) to identify the virus.
Data analyses. Statistical analyses were performed using SPSS, version 12.0 (SPSS, Chicago, IL). Logistic regression was used to estimate the odds ratio for laboratory-confirmed influenza in vaccinated versus unvaccinated subjects. Vaccine effectiveness (VE) was defined as 100 ϫ (1 Ϫ odds ratio for influenza in vaccinated versus nonvaccinated persons) according to previous similar study protocols (7) . Logistic regression models were adjusted for age, smoker status, and comorbidities. The significant difference in the distribution of variables between cases and controls was estimated by the chi-square or Fisher's exact test for categorical variables and Student's t test for quantitative variables. A bilateral P value of Ͻ0.05 was considered a significant result.
Review of the research plan. The study was performed with the approval of the institutional review board (IRB) from each of the four hospitals. The requirement for written informed consent was waived because most of the data were collected retrospectively by reviewing medical records. A telephone interview was done only for checking the 2010-2011 seasonal influenza vaccination history. If a subject refused to have a telephone interview, the subject was excluded from the analysis.
RESULTS
During the study period, a total of 796 ILI patients were diagnosed with laboratory-confirmed influenza. Among these patients, 313 patients were excluded due to an obscure influenza vaccination history. As a result, a total of 1,449 subjects were included in this study: 483 cases in each group (Table 1) . Among the case subjects, 473 (97.9%) subjects were tested with RAT and 435 (90.1%) subjects were positive for influenza virus, 114 (23.6%) subjects were tested with PCR and 98 (86.0%) subjects were positive for influenza virus, and 69 (14.2%) subjects were tested with virus culture and 48 (69.6%) subjects were positive for influenza virus. Among the control 1 subjects, 470 (97.3%) subjects were tested with RAT, 53 (11.0%) subjects were tested with PCR, and 66 (13.7%) subjects were tested with virus culture.
Among the case subjects, 473 (97.9%) subjects were positive for influenza A virus, 9 (1.9%) subjects were positive for influenza B virus, and 1 (0.2%) subject was positive for both influenza A and B viruses. Among the patients in the three groups, 981 (67.7%) patients were younger than 50 years of age, 309 (21.3%) patients were 50 to 64 years of age, and 159 (11.0%) patients were Ն65 years of age. Five hundred eight-three (40.2%) patients were male, and 543 (37.5%) patients had one or more underlying diseases. There was no significant difference in gender among the three groups, but chronic medical conditions were more common in control 2 patients. Among the 1,449 subjects, 273 (18.8%) were vaccinated with a dose of 2010-2011 seasonal influenza vaccine. In univariate analysis, the influenza vaccination rate was significantly higher in both control 1 and 2 patients than in the case group (P Ͻ 0.01 for both comparisons). For control 1, the VE of the 2010-2011 seasonal influenza vaccine was calculated to be 49.5% (95% confidence interval [CI], 30.4% to 63.3%) for influenza A and B viruses and 50.8% (95% CI, 31.9% to 64.4%) for influenza A virus (Table 2) . For control 2, the VE of the 2010-2011 seasonal influenza vaccine was calculated to be 45.8% (95% CI, 24.6% to 61.1%) for influenza A and B viruses and 47.2% (95% CI, 26.0% to 62.3%) for influenza A virus. The age-specific adjusted VE was 50.8% (95% CI, 25.1% to 67.7%) to 46.5% (95% CI, 16.6% to 65.6%) among subjects aged 19 to 49 years, 58.7% (95% CI, 16.9% to 79.5%) to 63.3% (95% CI, 26.0% to 81.8%) among those aged 50 to 64 years, and 0.2% (95% CI, Ϫ155.8% to 61.1%) to 53.0% (95% CI, Ϫ31.8% to 83.2%) among those aged 65 years or more (Table 3) .
DISCUSSION
The study findings indicate that the 2010-2011 seasonal influenza vaccine was effective for preventing laboratory-confirmed influenza, especially for influenza A virus, in adults younger than 65 years of age. However, the influenza vaccine was not effective in the elderly or against influenza B virus. Because the main epidemic strain in the 2010-2011 season was influenza A virus, the number of case patients with laboratory-confirmed influenza B virus infection was too small to show the effectiveness of the influenza vaccine against influenza B virus. For the elderly, however, the present data indicate the limited effectiveness of the 2010-2011 seasonal influenza vaccine. A similar result was shown in another study performed in Europe during the same season (8) . The low level of effectiveness of the seasonal influenza vaccine in the elderly for the prevention of influenza itself has been well documented (9-11), although a reduction in influenza-associated morbidity and mortality has been shown with influenza vaccination in the elderly. Recently, several types of vaccines, including an adjuvant-containing, high-dose, and intradermal vaccine, were developed for the elderly to overcome these limitations. In South Korea, almost all of the influenza vaccines used for the elderly are the traditional unadjuvanted split vaccine. During the 2010-2011 season, 95.2% of influenza vaccines approved for use by the South Korea Food and Drug Administration were traditional unadjuvanted split vaccines (http://www.kfda.go.kr/index.kfda?mid ϭ50&cmdϭv&seqϭ16220). Therefore, we have to carefully consider the use of adjuvanted, intradermal, or high-dose vaccines for the elderly if the cost-benefit of those vaccines is proven (9) .
For influenza A virus, the 2010-2011 seasonal influenza vaccine showed a deteriorated effectiveness compared with that of the pandemic influenza A/H1N1 2009pdm monovalent vaccine. In a previous study evaluating the effectiveness of the pandemic influenza vaccine using similar methods, the overall VE against the A/H1N1 2009pdm virus was 73.4%, although the age-specific VE was not identified for adults (7) . The main epidemic strain in the 2010-2011 season was the A/H1N1 2009pdm virus. Because a large segment of the population was vaccinated with the pandemic influenza vaccine when the pandemic influenza occurred, a large portion of the study subjects might have already been exposed to the A/H1N1 2009pdm virus through natural infection or vaccination. The pandemic influenza vaccination rate in South Korea was 26.1% for the total population and 54.4% for priority groups targeted by a national vaccination campaign (12) . If many control subjects were exposed to the A/H1N1 2009pdm virus, it could have influenced the results of this study, by manifesting as an apparent deteriorated effectiveness of the influenza vaccine. We could not draw a conclusion on that issue because we did not check the pandemic influenza infection or vaccination history of the subjects. In this study, we used two kinds of controls. Control 1 has generally been used in analyzing the effectiveness of the influenza vaccine in preventing laboratory-confirmed influenza. However, this has a limitation, in that some subjects are true influenza patients with false-negative results, especially with the RAT (13) (14) (15) (16) . This can produce a biased estimation of the effectiveness of the influenza vaccine. To minimize this limitation, we introduced control 2 in this analysis. Control 2 patients were non-ILI patients who visited the selected hospitals without an ILI. In fact, the control 2 subjects were not representative of cases, and they had more comorbidities than the case or control 1 subjects. When we compared the results of the analyses with control 1 and 2 subjects, there was no obvious difference except in those in the age group Ն65 years old. The adjusted VE in that age group showed different results according to the kinds of controls. This difference is due to the difference of the proportion of the comorbidities.
This study had several limitations. First, among the control subjects, some may have been influenza patients because they showed false-negative results or asymptomatic status. The RAT is well-known to have low sensitivity, especially for patients who take the test after Ն3 days of symptom onset (14) . To minimize the false-negative results, however, control 1 subjects were restricted to patients with an ILI who visited the same hospital within 48 h of symptom onset in this study. Second, this study focused on the effect of the influenza vaccine on the occurrence of laboratory-confirmed influenza. Although the influenza vaccine was not found to be effective in older adults in this study, the influenza vaccine could reduce influenza-associated morbidity and mortality in that population. A study performed in Spain reported that the 2010-2011 influenza vaccine had a moderate effect in preventing hospitalization in the at-risk population (17) . Third, we did not check the A/H1N1 2009pdm virus vaccination or infection history. During the pandemic period, the South Korea Centers for Disease Control and Prevention recommended that healthy people with flu-like symptoms seek medical attention only if they had influenza-related complications or were getting worse. Therefore, a considerable number of influenza patients might not be diagnosed with pandemic influenza. In addition, the pandemic influenza vaccine was given at various health care institutions, and the individual vaccination history could be checked only through personal interview. The authors decided not to check the A/H1N1 2009pdm vaccination or infection history, considering the unreliability of the data. Lastly, it would be useful to apply the results of this study to the traditional unadjuvanted split influenza vaccine. Other types of influenza vaccines, such as the adjuvanted vaccine or the high-dose vaccine, may show different results.
In conclusion, the 2010-2011 seasonal influenza vaccine was effective for preventing laboratory-confirmed influenza, especially for influenza A virus, in a South Korean adult population. However, evidence of the effectiveness of the influenza vaccine in the elderly or against influenza B virus was not found. For the elderly, in particular, the use of next-generation influenza vaccines such as adjuvanted, intradermal, or high-dose vaccines should be considered if improved effectiveness and cost-effectiveness are proven.
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